'Diet and lifestyle' in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members
Atheroscler Suppl. 2020 Dec;42:e9-e14. doi: 10.1016/j.atherosclerosissup.2021.01.003.ABSTRACTTo better understand the level of knowledge and interest in 'diet and lifestyle' for cholesterol management and CVD prevention, European Atherosclerosis Society (EAS) members were invited to take part in an online survey. In total, 269 EAS members participated of which 64 (24%) were students/postdocs, 102 (38%) researchers involved with CVD-related research and 103 (38%) doctors and clinicians who directly interact with patients. All (99%) of the participants either agreed or strongly agreed that 'diet and lifestyle' have a role to...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Elke A Trautwein Alberico L Catapano Lale Tokg özoğlu Source Type: research
Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk
Atheroscler Suppl. 2020 Dec;42:e1-e5. doi: 10.1016/j.atherosclerosissup.2021.01.001.ABSTRACTThe 2018 American Heart Association/American College of Cardiology/Multi-Society (AHA/ACC/MS) Guideline on the Management of Blood Cholesterol and the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the Management of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk, that were recently released by the United States and Europe, provide new recommendations for the management of blood lipid levels based on the latest evidence. Despite many common points, there are several diff...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Lale Tokg özoğlu Manuela Casula Angela Pirillo Alberico L Catapano Source Type: research
The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study
CONCLUSIONS: The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more common in men than in women. The most common CV risk factors are excess waist circumference, dyslipidaemia and HTN. Family physicians should conduct activities to prevent, diagnose early and treat CVD in the primary health care population.PMID:33589219 | DOI:10.1016/j.atherosclerosissup.2021.01.004 (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Jacek J J óźwiak Krzysztof Studzi ński Tomasz Tomasik Adam Windak Miros ław Mastej Alberico L Catapano Kausik K Ray Dimitri P Mikhailidis Peter P Toth George Howard Gregory Y H Lip Maciej Tomaszewski Fadi J Charchar Naveed Sattar Bryan Williams Thomas Source Type: research
Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy
Atheroscler Suppl. 2020 Dec;42:e25-e29. doi: 10.1016/j.atherosclerosissup.2021.01.005.ABSTRACTThe availability of efficient lipid-lowering drugs has substantially reduced the incidence and mortality for cardiovascular disease (CVD). Despite that, CVD still represents a major cause of death and disability; efforts are thus required to prevent this disease, since reducing the established CV risk factors may slow or prevent the onset of cardiovascular events. Current guidelines recommend a healthier lifestyle for all CV risk categories, as it may have a beneficial impact on several risk factors; in individuals with a low-to-m...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Bernhard F öger Catriona Jennings Angela Pirillo Lale Tokg özoğlu Matteo Pirro Alberico L Catapano Source Type: research
Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients
Atheroscler Suppl. 2020 Dec;42:e30-e34. doi: 10.1016/j.atherosclerosissup.2021.01.006.ABSTRACTThe widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have rev...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Gerald F Watts Alberico L Catapano Luis Masana Alberto Zambon Angela Pirillo Lale Tokg özoğlu Source Type: research
